Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future.

摘要: During the past decade important progress has been made regarding pathogenesis of idiopathic pulmonary fibrosis (IPF), which is most devastating form interstitial pneumonia with a median survival 3 years. The knowledge gained used to design multicentre, randomised, placebo-controlled trials in order investigate agents different mechanisms action. Encouraging results have led licensing first IPF-specific drug, pirfenidone. However, road successful treatment still long. main aim for future should be careful clinical trials, by choosing clinically meaningful end-point and keeping mind that combination various may more effective. This approach lung cancer IPF presents many similarities.